Teva Pharmaceutical Industries Ltd (TEVA.K)
22 Sep 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|70||2017||Chairman of the Board|
|66||2017||Interim President and Chief Executive Officer|
|56||President, Chief Executive Officer|
|65||2014||Group Executive Vice President, Chief Financial Officer|
|56||2016||President and Chief Executive Officer-Global Generic Medicines Group|
- LPC: Banks line up €430m loan for CVC’s Teva asset buy
- UPDATE 1-LPC-Banks line up €430m loan for CVC’s Teva asset buy
- BRIEF-Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states
- LPC-Banks line up €430m loan for CVC’s Teva asset buy
- Fitch Affirms Jubilant Pharma at 'BB-'; Outlook Stable